Insmed, Inc. (NASDAQ:INSM) Receives $129.57 Consensus Price Target from Analysts

Key Points

• Insmed, Inc. has received a consensus recommendation of "Moderate Buy" from sixteen research firms, with an average one-year price target of $129.57.
• Recent analyst reports indicate price target increases, with Stifel Nicolaus raising their target from $121 to $145 and Mizuho from $130 to $165.
• Insider trading has been notable, with CEO William Lewis selling 129,805 shares for over $13 million, indicating significant shifts in insider holdings.

Shares of Insmed, Inc. (NASDAQ:INSM - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seventeen research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $132.5714.

Several research firms have recently weighed in on INSM. Jefferies Financial Group boosted their price target on Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a report on Wednesday, August 13th. JPMorgan Chase & Co. boosted their price target on Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a report on Wednesday. Mizuho upped their target price on Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. William Blair initiated coverage on Insmed in a report on Wednesday. They issued an "outperform" rating on the stock. Finally, Royal Bank Of Canada upped their target price on Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a report on Friday, August 8th.

Insmed Trading Down 0.5%

Shares of NASDAQ:INSM traded down $0.72 during midday trading on Wednesday, hitting $131.88. 2,098,219 shares of the stock were exchanged, compared to its average volume of 2,822,436. The stock has a market capitalization of $27.88 billion, a price-to-earnings ratio of -23.10 and a beta of 0.95. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The business's 50-day moving average price is $106.82 and its 200 day moving average price is $85.31. Insmed has a 12 month low of $60.40 and a 12 month high of $133.56.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The firm had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter last year, the firm posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. Analysts predict that Insmed will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 129,805 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the transaction, the chief executive officer directly owned 233,924 shares of the company's stock, valued at $23,483,630.36. This represents a 35.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $129.50, for a total value of $1,295,000.00. Following the transaction, the director directly owned 274,516 shares in the company, valued at $35,549,822. The trade was a 3.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 539,694 shares of company stock valued at $53,144,604. 3.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Insmed

A number of institutional investors have recently modified their holdings of INSM. B. Riley Wealth Advisors Inc. purchased a new stake in Insmed in the 2nd quarter valued at $291,000. CANADA LIFE ASSURANCE Co raised its position in Insmed by 8.9% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 46,250 shares of the biopharmaceutical company's stock valued at $4,664,000 after buying an additional 3,792 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Insmed by 510.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 45,235 shares of the biopharmaceutical company's stock valued at $4,552,000 after buying an additional 37,820 shares during the last quarter. Corient Private Wealth LLC raised its position in Insmed by 22.0% in the 2nd quarter. Corient Private Wealth LLC now owns 15,024 shares of the biopharmaceutical company's stock valued at $1,515,000 after buying an additional 2,705 shares during the last quarter. Finally, Sender Co & Partners Inc. purchased a new stake in Insmed in the 2nd quarter valued at $218,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.